Ignite Creation Date:
2025-12-24 @ 11:32 PM
Ignite Modification Date:
2025-12-25 @ 9:20 PM
Study NCT ID:
NCT05471856
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2022-07-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-24
Start Date Type:
ACTUAL
Primary Completion Date:
2028-09-13
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-09-13
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-21
First Submit QC Date:
None
Study First Post Date:
2022-07-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-16
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED